SONN Insider Trading

Insider Ownership Percentage: 2.00%
Insider Buying (Last 12 Months): $17,920.98
Insider Selling (Last 12 Months): $0.00

Sonnet BioTherapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Sonnet BioTherapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Sonnet BioTherapeutics Share Price & Price History

Current Price: $1.74
Price Change: Price Increase of +0.09 (5.45%)
As of 05/22/2024 05:15 PM ET

This chart shows the closing price history over time for SONN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Sonnet BioTherapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/14/2023Susan DexterInsiderBuy454$15.40$6,991.601,530View SEC Filing Icon  
5/30/2023Albert D DyrnessDirectorBuy1,057$10.34$10,929.381,316View SEC Filing Icon  
5/17/2023Nailesh BhattDirectorBuy1,136$5.06$5,748.161,396View SEC Filing Icon  
5/15/2023Pankaj MohanCEOBuy16,890$4.84$81,747.6025,151View SEC Filing Icon  
6/9/2021Pankaj MohanCEOBuy1,454$34.10$49,581.40View SEC Filing Icon  
6/9/2021Richard T. KenneyInsiderBuy681$33.88$23,072.28View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Sonnet BioTherapeutics (NASDAQ:SONN)

9.45% of Sonnet BioTherapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at SONN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Sonnet BioTherapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
7/27/2023Virtu Financial LLC86,624$42K0.0%N/A0.315%Search for SEC Filing on Google Icon
5/19/2023Anson Funds Management LP1,760,000$0.63M0.1%N/A6.405%Search for SEC Filing on Google Icon
11/7/2022Virtu Financial LLC26,914$40K0.0%N/A0.622%Search for SEC Filing on Google Icon
8/2/2022Advisory Services Network LLC130,525$37K0.0%+158.3%0.215%Search for SEC Filing on Google Icon
5/10/2022Campion Asset Management90,612$34K0.0%N/A0.150%Search for SEC Filing on Google Icon
8/16/2021State Street Corp62,688$99K0.0%N/A0.253%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.701,634$1.11M0.0%+416.0%2.834%Search for SEC Filing on Google Icon
5/19/2021Virtu Financial LLC65,106$0.15M0.0%N/A0.371%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC113,264$0.26M0.0%N/A0.534%Search for SEC Filing on Google Icon
5/18/2021Jane Street Group LLC17,304$39K0.0%N/A0.099%Search for SEC Filing on Google Icon
5/17/2021Price T Rowe Associates Inc. MD45,100$0.10M0.0%N/A0.257%Search for SEC Filing on Google Icon
5/13/2021Bank of New York Mellon Corp20,399$46K0.0%N/A0.116%Search for SEC Filing on Google Icon
5/7/2021BlackRock Inc.255,761$0.58M0.0%+3.7%1.457%Search for SEC Filing on Google Icon
3/26/2021Susquehanna International Group LLP15,434$34K0.0%N/A0.088%Search for SEC Filing on Google Icon
2/9/2021Advisory Services Network LLC24,581$55K0.0%+32.3%0.143%Search for SEC Filing on Google Icon
2/5/2021BlackRock Inc.246,555$0.55M0.0%+2.5%1.435%Search for SEC Filing on Google Icon
11/19/2020Schonfeld Strategic Advisors LLC12,200$31K0.0%N/A0.071%Search for SEC Filing on Google Icon
11/19/2020IHT Wealth Management LLC10,000$26K0.0%N/A0.058%Search for SEC Filing on Google Icon
11/17/2020Schonfeld Strategic Advisors LLC12,200$31K0.0%N/A0.089%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Sonnet BioTherapeutics logo
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.
Read More on Sonnet BioTherapeutics

Today's Range

Now: $1.74
Low: $1.63
High: $1.78

50 Day Range

MA: $1.88
Low: $1.65
High: $2.26

52 Week Range

Now: $1.74
Low: $1.08
High: $26.40


45,560 shs

Average Volume

74,819 shs

Market Capitalization

$5.41 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Sonnet BioTherapeutics?

Sonnet BioTherapeutics' top insider investors include:
  1. Pankaj Mohan (CEO)
  2. Susan Dexter (Insider)
  3. Nailesh Bhatt (Director)
  4. Albert D Dyrness (Director)
Learn More about top insider investors at Sonnet BioTherapeutics.